Klastersky J, Van Beerse D, Schoutens E, De Temmerman P, Yourassowsky E
J Clin Pharmacol. 1976 Apr;16(4):213-22. doi: 10.1002/j.1552-4604.1976.tb01520.x.
Amikacin was administered to 51 patients with serious Gram-negative infections. A favorable clinical outcome was observed in 32 patients (62 per cent). No major untoward effects were noted. The severity of the underlying disease and the site of the infection were important for the outcome. Urinary tract infections responded in 21 (78 per cent) out of 27 patients, but bronchopulmonary infections responded in only 3 out of 10 patients (30 per cent). The degree of antibacterial activity of the serum of the patients receiving amikacin was found to be related to the outcome. An activity greater than or equal to 1/8 was associated with 78 per cent of favorable responses and was found more often in patients receiving 1500 mg daily.
对51例严重革兰氏阴性菌感染患者使用了阿米卡星。32例患者（62%）观察到了良好的临床结果。未发现重大不良反应。基础疾病的严重程度和感染部位对结果很重要。27例尿路感染患者中有21例（78%）有反应，但10例支气管肺部感染患者中只有3例（30%）有反应。发现接受阿米卡星治疗患者血清的抗菌活性程度与结果相关。活性大于或等于1/8与78%的良好反应相关，且在每日接受1500毫克治疗的患者中更常出现。
